Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abrocitinib
Drug ID BADD_D02527
Description Abrocitinib is under investigation in clinical trial NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).
Indications and Usage Not Available
Marketing Status investigational
ATC Code D11AH08
DrugBank ID DB14973
KEGG ID D11400
MeSH ID C000634427
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 53869-1335; 0069-0235; 63539-236; 63539-336; 63539-436; 53869-1435; 0069-0335; 0069-0435; 53869-1235
UNII 73SM5SF3OR
Synonyms abrocitinib | N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide | N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide | 1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)- | PF-04965842
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1622902-68-4
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.0020.000390%
Abdominal pain upper07.01.05.0030.000603%
Acne23.02.01.0010.001596%Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.000993%Not Available
Cataract06.06.01.001--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000390%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000780%Not Available
Condition aggravated08.01.03.0040.003759%Not Available
Cough22.02.03.001--
Dermatitis atopic23.03.04.016; 10.01.04.0040.001986%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000869%
Drug hypersensitivity10.01.01.0010.000904%Not Available
Drug ineffective08.06.01.0060.006898%Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Eczema23.03.04.0060.000692%
Epistaxis24.07.01.005; 22.04.03.001--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.000390%Not Available
Flatulence07.01.04.002--
Hair growth abnormal23.02.06.0060.000603%Not Available
Hypertension24.08.02.0010.000177%
Insomnia19.02.01.002; 17.15.03.0020.000177%
Nausea07.01.07.0010.003103%
Neurodermatitis23.03.04.0070.000603%Not Available
Palpitations02.11.04.0120.000390%
Pruritus23.03.12.0010.002589%
Psoriasis10.02.01.036; 23.03.14.0020.000390%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages